The multidisciplinary European Joint Doctorate programme "MINDSHIFT" (www.eumindshift.eu) – started on January 1 and is made possible by a European grant of over four million euros from the European Union’s Horizon 2020 research and innovation programme.
MINDSHIFT offers a unique training programme in the fields of clinical-epidemiological hypertension research, vascular and endocrine pathophysiology, genetics and genomics, and ageing, focussed on personal development, leading to a joint or double doctorate.
Led by Maastricht UMC+ and Maastricht University the four-year programme, includes 14 other partners from the United Kingdom, Spain, Italy, France, Austria, Switzerland and Poland.
The collaborative network includes academic institutions, research centres and industry with specific expertise and interest in hypertension that. Over the next few years the network will unravel new mechanisms of hypertension and will advance knowledge in the field.
The ICAMS team will be contributing to four projects within the MINDSHIFT programme. Early stage researchers will be supervised by clinical and basic scientists within the College of MVLS and closely collaborate with other consortium partners across Europe.
Prof. Rhian Touyz will study the molecular make-up of small blood vessels and how they contribute to the development of high blood pressure.
Prof. Christian Delles will study how hypertension leads to damage of the heart, kidneys and other organs and why some patients are more affected than others.
Prof. Eleanor Davies will dissect the role of aldosterone in the development of hypertension and how this hormone is regulated by small RNA molecules.
Prof. Paul Shiels (Institute of Cancer Sciences) will put hypertension into the context of ageing, and will develop new treatments to interfere with the ageing process.
European Union's Horizon 2020
This project has received funding
from the European Union’s Horizon
2020 research and innovation
programme under the Marie
Skłodowska-Curie grant agreement
MINDSHIFT is coordinated by
CARIM, School for Cardiovascular
Diseases at Maastricht University,